Amal Ayyoub
Research Subjects
Amal Ayyoub has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Castañón Álvarez
Clinica Universidad de Navarra 4 Department of Oncology Pamplona, Spain
24 shared publications - Enriqueta Felip
Vall d’Hebron University Hospital, Barcelona, Spain
24 shared publications - Ikbel Achour
AstraZeneca 16 , Gaithersburg, Maryland
24 shared publications - Michael Kuziora
AstraZeneca 16 , Gaithersburg, Maryland
24 shared publications - Sang-We Kim
Department of Oncology, Asan Medical Center, Seoul, Republic of Korea
24 shared publications - Ben Tran
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
13 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
Purpose: Dosage modifications, including dose interruptions and reductions, are commonly implemented to manage adverse reactions observed with oncology drugs. However, their impact on efficacy is not well understood. Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: We collected patient-level data from clinical trials supporting the original FDA approvals of afatinib, dacomitinib, mobocertinib, and osimertinib. We identified the daily dose received (DDR; a measure of the dosage received by a patient each day), dose interruptions and reductions over the treatment period. In this exploratory analysis, we used a time-dependent Cox proportional hazards model to assess the impact of DDR on PFS and landmark time-fixed Cox models at 30, 60, and 90 days from treatment initiation to assess the impact of early dose interruptions and reductions on PFS and OS.Results: While the impact of dose interruptions and reductions on the risk of death varied among the studied drugs, dose interruptions, such as interruptions for four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. Conclusion: For the evaluated drugs as monotherapy in NSCLC with EGFR mutations, our analysis suggests that dose reductions might have a lower impact on efficacy than missing or interrupting treatment. Further studies are needed to evaluate other EGFR treatments, drug classes, and cancer types.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
Purpose: Dosage modifications, including dose interruptions and reductions, are commonly implemented to manage adverse reactions observed with oncology drugs. However, their impact on efficacy is not well understood. Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: We collected patient-level data from clinical trials supporting the original FDA approvals of afatinib, dacomitinib, mobocertinib, and osimertinib. We identified the daily dose received (DDR; a measure of the dosage received by a patient each day), dose interruptions and reductions over the treatment period. In this exploratory analysis, we used a time-dependent Cox proportional hazards model to assess the impact of DDR on PFS and landmark time-fixed Cox models at 30, 60, and 90 days from treatment initiation to assess the impact of early dose interruptions and reductions on PFS and OS.Results: While the impact of dose interruptions and reductions on the risk of death varied among the studied drugs, dose interruptions, such as interruptions for four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. Conclusion: For the evaluated drugs as monotherapy in NSCLC with EGFR mutations, our analysis suggests that dose reductions might have a lower impact on efficacy than missing or interrupting treatment. Further studies are needed to evaluate other EGFR treatments, drug classes, and cancer types.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Geometric mean serum concentration-time profiles of rilvegostomig by dose (PK analysis set).
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Geometric mean serum concentration-time profiles of rilvegostomig by dose (PK analysis set).
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient disposition in Part A and Part B of ARTEMIDE-01.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient disposition in Part A and Part B of ARTEMIDE-01.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Kaplan-Meier plot of PFS with rilvegostomig.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Kaplan-Meier plot of PFS with rilvegostomig.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Inclusion and exclusion criteria for Parts A and B of ARTEMIDE-01 study.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Inclusion and exclusion criteria for Parts A and B of ARTEMIDE-01 study.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Supplementary Methods and Materials.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Supplementary Methods and Materials.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient demographics and baseline disease characteristics in Part A by dose level.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient demographics and baseline disease characteristics in Part A by dose level.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Representativeness of study participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Representativeness of study participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of rilvegostomig safety profile in Part A by dose level.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of rilvegostomig safety profile in Part A by dose level.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Anti-drug antibody responses (immunogenicity analysis set).
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Anti-drug antibody responses (immunogenicity analysis set).